Tumor metastasis to bone

Arthritis Research and Therapy

Volumn 9, Issue SUPPL.1, 2007, Pages

  Virk, Mandeep S ^a   Lieberman, Jay R ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; BONE MORPHOGENETIC PROTEIN; CILENGITIDE; COLONY STIMULATING FACTOR 1; DENOSUMAB; ENDOTHELIN 1; IMATINIB; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; OLIGODEOXYNUCLEOTIDE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN; PLACEBO; PROSTAGLANDIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; WNT1 PROTEIN;

BONE LESION; BONE MATRIX; BONE METABOLISM; BONE METASTASIS; BONE TUMOR; BONE TURNOVER; CANCER INHIBITION; CELL ACTIVATION; CELL CYCLE; CELL DIFFERENTIATION; CELL INTERACTION; CELL PROLIFERATION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG EFFICACY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; REVIEW; SINGLE DRUG DOSE; TUMOR CELL; TUMOR GROWTH; ANIMAL; METABOLISM; METASTASIS; OSTEOBLAST; PATHOLOGY;

ANIMALS; BONE NEOPLASMS; HUMANS; OSTEOBLASTS;

EID: 34548412731     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2169     Document Type: Review

References (99)

1. American Cancer Society Cancer Facts and Figures, 2007 Atlanta: American Cancer Society 2007 http://www.cancer.org/downloads/STT/ CAFF2007PWSecured.pdf
2. Coleman RE Metastatic bone disease: Clinical features, pathophysiology and treatment strategies Cancer Treat Rev 2001, 27:165-176. 10.1053/ ctrv.2000.0210 11417967
3. Coleman RE Skeletal complications of malignancy Cancer 1997, (Suppl):1588-1594. 10.1002/(SICI)1097-0142(19971015)80:8+ <1588::AID-CNCR9>3.0.CO;2-G
4. Roodman GD Mechanisms of bone metastasis N Engl J Med 2004, 350:1655-1664. 10.1056/NEJMra030831 15084698
5. Mundy GR Metastasis to bone: Causes, consequences and therapeutic opportunities Nat Rev Cancer 2002, 2:584-593. 10.1038/nrc867 12154351
6. Paget S The distribution of secondary growths in cancer of the breast. 1889 Cancer Metastasis Rev 1989, 8:98-101. 2673568
7. Steeg PS Tumor metastasis: Mechanistic insights and clinical challenges Nat Med 2006, 12:895-904. 10.1038/nm1469 16892035
8. Hoon DS Kitago M Kim J Mori T Piris A Szyfelbein K Mihm MC Jr Nathanson SD Padera TP Chambers AF Molecular mechanisms of metastasis Cancer Metastasis Rev 2006, 25:203-220. 10.1007/s10555-006-8500-x 16770533
9. Mastro AM Gay CV Welch DR The skeleton as a unique environment for breast cancer cells Clin Exp Metastasis 2003, 20:275-284. 10.1023/ A:1022995403081 12741685
10. Chambers AF Groom AC MacDonald IC Dissemination and growth of cancer cells in metastatic sites Nat Rev Cancer 2002, 2:563-572. 10.1038/nrc865 12154349
11. Fidler IJ Kripke ML Metastasis results from preexisting variant cells within a malignant tumor Science 1977, 197:893-895. 10.1126/ science.887927 887927
12. van't Veer LJ Dai H van de Vijver MJ He YD Hart AA Mao M Peterse HL van der Kooy K Marton MJ Witteveen AT Gene expression profiling predicts clinical outcome of breast cancer Nature 2002, 415:530-536. 10.1038/ 415530a 11823860
13. Bernards R Weinberg RA A progression puzzle Nature 2002, 418-823. 10.1038/418823a 12192390
14. Ramaswamy S Ross KN Lander ES Golub TR A molecular signature of metastasis in primary solid tumors Nat Genet 2003, 33:49-54. 10.1038/ ng1060 12469122
15. Kang Y Siegel PM Shu W Drobnjak M Kakonen SM Cordon-Cardo C Guise TA Massague J A multigenic program mediating breast cancer metastasis to bone Cancer Cell 2003, 3:537-549. 10.1016/S1535-6108(03)00132-6 12842083
16. Smid M Wang Y Klijn JG Sieuwerts AM Zhang Y Atkins D Martens JW Foekens JA Genes associated with breast cancer metastatic to bone J Clin Oncol 2006, 24:2261-2267. 10.1200/JCO.2005.03.8802 16636340
17. Schneider A Kalikin LM Mattos AC Keller ET Allen MJ Pienta KJ McCauley LK Bone turnover mediates preferential localization of prostate cancer in the skeleton Endocrinology 2005, 146:1727-1736. 10.1210/en.2004-1211 15637291
18. Phadke PA Mercer RR Harms JF Jia Y Frost AR Jewell JL Bussard KM Nelson S Moore C Kappes JC Kinetics of metastatic breast cancer cell trafficking in bone Clin Cancer Res 2006, 12:1431-1440. 1523260 16533765 10.1158/1078-0432.CCR-05-1806
19. Kaplan RN Riba RD Zacharoulis S Bramley AH Vincent L Costa C MacDonald DD Jin DK Shido K Kerns SA VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche Nature 2005, 438:820-827. 10.1038/nature04186 16341007
20. Pirtskhalaishvili G Nelson JB Endothelium-derived factors as paracrine mediators of prostate cancer progression Prostate 2000, 44:77-87. 10.1002/1097-0045(20000615)44:1<77::AID-PROS10>3.0.CO;2-G 10861760
21. Yoneda T Hiraga T Crosstalk between cancer cells and bone microenvironment in bone metastasis Biochem Biophys Res Commun 2005, 328:679-687. 10.1016/j.bbrc.2004.11.070 15694401
22. Zhang JH Wang J Tang J Barnett B Dickson J Hahsimoto N Williams P Ma W Zheng W Yoneda T Bone sialoprotein promotes bone metastasis of a non-bone-seeking clone of human breast cancer cells Anticancer Res 2004, 24:1361-1368. 15274296
23. Stewart DA Cooper CR Sikes RA Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer Reprod Biol Endocrinol 2004, 2:2. 320496 14711377 10.1186/1477-7827-2-2
24. Hauschka PV Mavrakos AE Iafrati MD Doleman SE Klagsbrun M Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-sepharose J Biol Chem 1986, 261:12665-12674. 3745206
25. Feeley BT Gamradt SC Hsu WK Liu N Krenek L Robbins P Huard J Lieberman JR Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer J Bone Miner Res 2005, 20:2189-2199. 10.1359/ JBMR.050802 16294272
26. Guise TA Kozlow WM Heras-Herzig A Padalecki SS Yin JJ Chirgwin JM Molecular mechanisms of breast cancer metastases to bone Clin Breast Cancer 2005, (Suppl 2):S46-S53.
27. Yin JJ Pollock CB Kelly K Mechanisms of cancer metastasis to the bone Cell Res 2005, 15:57-62. 10.1038/sj.cr.7290266 15686629
28. Lee Y Schwarz E Davies M Jo M Gates J Wu J Zhang X Lieberman JR Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone J Orthop Res 2003, 21:62-72. 10.1016/S0736-0266(02)00095-5 12507581
29. Pederson L Winding B Foged NT Spelsberg TC Oursler MJ Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity Cancer Res 1999, 59:5849-5855. 10582709
30. Shimamura T Amizuka N Li M Freitas PH White JH Henderson JE Shingaki S Nakajima T Ozawa H Histological observations on the microenvironment of osteolytic bone metastasis by breast carcinoma cell line Biomed Res 2005, 26:159-172. 10.2220/biomedres.26.159 16152732
31. Roodman GD Regulation of osteoclast differentiation Ann N Y Acad Sci 2006, 1068:100-109. 10.1196/annals.1346.013 16831910
32. Boyle WJ Simonet WS Lacey DL Osteoclast differentiation and activation Nature 2003, 423:337-342. 10.1038/nature01658 12748652
33. Hofbauer LC Neubauer A Heufelder AE Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: Potential implications for the pathogenesis and treatment of malignant bone diseases Cancer 2001, 92:460-470. 10.1002/ 1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D 11505389
34. Wittrant Y Theoleyre S Chipoy C Padrines M Blanchard F Heymann D Redini F RANKL/RANK/OPG: New therapeutic targets in bone tumours and associated osteolysis Biochim Biophys Acta 2004, 1704:49-57. 15363860
35. Lacey DL Timms E Tan HL Kelley MJ Dunstan CR Burgess T Elliott R Colombero A Elliott G Scully S Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 1998, 93:165-176. 10.1016/S0092-8674(00)81569-X 9568710
36. Ikeda T Kasai M Utsuyama M Hirokawa K Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus Endocrinology 2001, 142:1419-1426. 10.1210/en.142.4.1419 11250921
37. Anderson DM Maraskovsky E Billingsley WL Dougall WC Tometsko ME Roux ER Teepe MC DuBose RF Cosman D Galibert L A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function Nature 1997, 390:175-179. 10.1038/36593 9367155
38. Boyce BF Yamashita T Yao Z Zhang Q Li F Xing L Roles for NF-kappaB and c-Fos in osteoclasts J Bone Miner Metab 2005, (Suppl):11-15.
39. Simonet WS Lacey DL Dunstan CR Kelley M Chang MS Luthy R Nguyen HQ Wooden S Bennett L Boone T Osteoprotegerin: A novel secreted protein involved in the regulation of bone density Cell 1997, 89:309-319. 10.1016/S0092-8674(00)80209-3 9108485
40. Yasuda H Shima N Nakagawa N Yamaguchi K Kinosaki M Mochizuki S Tomoyasu A Yano K Goto M Murakami A Osteoclast differentiation factor is a ligand for osteoprote-gerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc Natl Acad Sci USA 1998, 95:3597-3602. 19881 9520411 10.1073/pnas.95.7.3597
41. Guise TA Yin JJ Taylor SD Kumagai Y Dallas M Boyce BF Yoneda T Mundy GR Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis J Clin Invest 1996, 98:1544-1549. 507586 8833902
42. Huang L Cheng YY Chow LT Zheng MH Kumta SM Tumour cells produce receptor activator of NF-kappaB ligand (RANKL) in skeletal metastases J Clin Pathol 2002, 55:877-878. 10.1136/jcp.55.11.877 12401833
43. Zhang J Dai J Yao Z Lu Y Dougall W Keller ET Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone Cancer Res 2003, 63:7883-7890. 14633717
44. Whang PG Schwarz EM Gamradt SC Dougall WC Lieberman JR The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone J Orthop Res 2005, 23:1475-1483. 16005175
45. Feeley BT Liu NQ Conduah AH Krenek L Roth K Dougall WC Huard J Dubinett S Lieberman JR Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and RANK:Fc administration J Bone Miner Res 2006, 21:1571-1580. 10.1359/jbmr.060706 16995812
46. Grimaud E Soubigou L Couillaud S Coipeau P Moreau A Passuti N Gouin F Redini F Heymann D Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis Am J Pathol 2003, 163:2021-2031. 1892410 14578201
47. Bendre MS Margulies AG Walser B Akel NS Bhattacharrya S Skinner RA Swain F Ramani V Mohammad KS Wessner LL Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway Cancer Res 2005, 65:11001-11009. 10.1158/ 0008-5472.CAN-05-2630 16322249
48. Kudo O Sabokbar A Pocock A Itonaga I Fujikawa Y Athanasou NA Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism Bone 2003, 32:1-7. 10.1016/ S8756-3282(02)00915-8 12584029
49. Itonaga I Sabokbar A Sun SG Kudo O Danks L Ferguson D Fujikawa Y Athanasou NA Transforming growth factor-beta induces osteoclast formation in the absence of RANKL Bone 2004, 34:57-64. 10.1016/ j.bone.2003.08.008 14751563
50. Loberg RD Logothetis CJ Keller ET Pienta KJ Pathogenesis and treatment of prostate cancer bone metastases: Targeting the lethal phenotype J Clin Oncol 2005, 23:8232-8241. 10.1200/JCO.2005.03.0841 16278478
51. Roland SI Calcium studies in ten cases of osteoblastic prostatic metastasis J Urol 1958, 79:339-342. 13514887
52. Hall CL Kang S MacDougald OA Keller ET Role of Wnts in prostate cancer bone metastases J Cell Biochem 2006, 97:661-672. 10.1002/jcb.20735 16447163
53. Kiefer JA Vessella RL Quinn JE Odman AM Zhang J Keller ET Kostenuik PJ Dunstan CR Corey E The effect of osteoprote-gerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft Clin Exp Metastasis 2004, 21:381-387. 10.1007/ s10585-004-2869-0 15672862
54. Lee YP Schwarz EM Davies M Jo M Gates J Zhang X Wu J Lieberman JR Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model Cancer Res 2002, 62:5564-5570. 12359769
55. Nelson JB Nguyen SH Wu-Wong JR Opgenorth TJ Dixon DB Chung LW Inoue N New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade Urology 1999, 53:1063-1069. 10.1016/S0090-4295(98)00658-X 10223507
56. Bodine PV Komm BS Wnt signaling and osteoblastogenesis Rev Endocr Metab Disord 2006, 7:33-39. 10.1007/s11154-006-9002-4 16960757
57. Chen G Shukeir N Potti A Sircar K Aprikian A Goltzman D Rabbani SA Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: Potential pathogenetic and prognostic implications Cancer 2004, 101:1345-1356. 10.1002/cncr.20518 15316903
58. Yin JJ Mohammad KS Kakonen SM Harris S Wu-Wong JR Wessale JL Padley RJ Garrett IR Chirgwin JM Guise TA A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases Proc Natl Acad Sci USA 2003, 100:10954-10959. 196909 12941866 10.1073/pnas.1830978100
59. Nelson JB Endothelin receptor antagonists World J Urol 2005, 23:19-27. 10.1007/s00345-004-0478-9 15654644
60. Stern PH Tatrai A Semler DE Lee SK Lakatos P Strieleman PJ Tarjan G Sanders JL Endothelin receptors, second messengers, and actions in bone J Nutr 1995, (Suppl):2028S-2032S.
61. Lieberman JR Daluiski A Einhorn TA The role of growth factors in the repair of bone. Biology and clinical applications J Bone Joint Surg Am 2002, 84-A:1032-1044. 12063342
62. Bentley H Hamdy FC Hart KA Seid JM Williams JL Johnstone D Russell RG Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia Br J Cancer 1992, 66:1159-1163. 1280991
63. Brubaker KD Corey E Brown LG Vessella RL Bone morphogenetic protein signaling in prostate cancer cell lines J Cell Biochem 2004, 91:151-160. 10.1002/jcb.10679 14689587
64. Masuda H Fukabori Y Nakano K Takezawa Y T CS Yamanaka H Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer Prostate 2003, 54:268-274. 10.1002/pros.10193 12539225
65. Bobinac D Maric I Zoricic S Spanjol J Dordevic G Mustac E Fuckar Z Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer Croat Med J 2005, 46:389-396. 15861517
66. Dai J Keller J Zhang J Lu Y Yao Z Keller ET Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism Cancer Res 2005, 65:8274-8285. 10.1158/0008-5472.CAN-05-1891 16166304
67. Rosol TJ Tannehill-Gregg SH LeRoy BE Mandl S Contag CH Animal models of bone metastasis Cancer 2003, (Suppl):748-757. 10.1002/cncr.11150
68. Yoneda T Sasaki A Dunstan C Williams PJ Bauss F De Clerck YA Mundy GR Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2 J Clin Invest 1997, 99:2509-2517. 508092 9153295
69. Body JJ Greipp P Coleman RE Facon T Geurs F Fermand JP Harousseau JL Lipton A Mariette X Williams CD A phase I study of AMGN-0007 a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases Cancer 2003, (Suppl):887-892. 10.1002/cncr.11138
70. Neville-Webbe HL Cross NA Eaton CL Nyambo R Evans CA Coleman RE Holen I Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis Breast Cancer Res Treat 2004, 86:269-279. 10.1023/B:BREA.0000036900.48763.b3 15567943
71. Abrahamsen B Teng AY Technology evaluation: Denosumab, Amgen Curr Opin Mol Ther 2005, 7:604-610. 16370384
72. Body JJ Facon T Coleman RE Lipton A Geurs F Fan M Holloway D Peterson MC Bekker PJ A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer Clin Cancer Res 2006, 12:1221-1228. 10.1158/1078-0432.CCR-05-1933 16489077
73. Carducci MA Jimeno A Targeting bone metastasis in prostate cancer with endothelin receptor antagonists Clin Cancer Res 2006, 12:6296s-6300s. 10.1158/1078-0432.CCR-06-0929 17062717
74. Murphy G Atrasentan for metastatic hormone refractory prostate cancer Issues Emerg Health Technol 2005, 77:1-4. 16544441
75. Dunehoo AL Anderson M Majumdar S Kobayashi N Berkland C Siahaan TJ Cell adhesion molecules for targeted drug delivery J Pharm Sci 2006, 95:1856-1872. 10.1002/jps.20676 16850395
76. Harms JF Welch DR Samant RS Shevde LA Miele ME Babu GR Goldberg SF Gilman VR Sosnowski DM Campo DA A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis Clin Exp Metastasis 2004, 21:119-128. 10.1023/B:CLIN.0000024763.69809.64 15168729
77. Kominsky SL Davidson NE A 'bone' fide predictor of metastasis? Predicting breast cancer metastasis to bone J Clin Oncol 2006, 24:2227-2229. 10.1200/JCO.2005.05.5319 16636338
78. Lee SK Gardner AE Kalinowski JF Jastrzebski SL Lorenzo JA RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production Bone 2006, 38:678-685. 10.1016/j.bone.2005.10.011 16309985
79. Jimi E Nakamura I Duong LT Ikebe T Takahashi N Rodan GA Suda T Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells Exp Cell Res 1999, 247:84-93. 10.1006/excr.1998.4320 10047450
80. Fuller K Murphy C Kirstein B Fox SW Chambers TJ TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL Endocrinology 2002, 143:1108-1118. 10.1210/en.143.3.1108 11861538
81. Lam J Takeshita S Barker JE Kanagawa O Ross FP Teitelbaum SL TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand J Clin Invest 2000, 106:1481-1488. 387259 11120755
82. Morgan H Tumber A Hill PA Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte/macrophage colony-stimulating factor Int J Cancer 2004, 109:653-660. 10.1002/ijc.20056 14999770
83. Mancino AT Klimberg VS Yamamoto M Manolagas SC Abe E Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells J Surg Res 2001, 100:18-24. 10.1006/jsre.2001.6204 11516200
84. Wani MR Fuller K Kim NS Choi Y Chambers T Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion Endocrinology 1999, 140:1927-1935. 10.1210/en.140.4.1927 10098533
85. Peyruchaud O Serre CM NicAmhlaoibh R Fournier P Clezardin P Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity J Biol Chem 2003, 278:45826-45832. 10.1074/ jbc.M309024200 12954626
86. Nemeth JA Yousif R Herzog M Che M Upadhyay J Shekarriz B Bhagat S Mullins C Fridman R Cher ML Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis J Natl Cancer Inst 2002, 94:17-25. 11773278
87. Fizazi K Yang J Peleg S Sikes CR Kreimann EL Daliani D Olive M Raymond KA Janus TJ Logothetis CJ Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts Clin Cancer Res 2003, 9:2587-2597. 12855635
88. Shariat SF Andrews B Kattan MW Kim J Wheeler TM Slawin KM Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis Urology 2001, 58:1008-1015. 10.1016/ S0090-4295(01)01405-4 11744478
89. Corey E Brown LG Kiefer JA Quinn JE Pitts TE Blair JM Vessella RL Osteoprotegerin in prostate cancer bone metastasis Cancer Res 2005, 65:1710-1718. 10.1158/0008-5472.CAN-04-2033 15753366
90. Matuo Y Nishi N Takasuka H Masuda Y Nishikawa K Isaacs JT Adams PS McKeehan WL Sato GH Production and significance of TGF-beta in AT-3 metastatic cell line established from the Dunning rat prostatic adenocarcinoma Biochem Biophys Res Commun 1990, 166:840-847. 10.1016/ 0006-291X(90)90886-R 2302241
91. Achbarou A Kaiser S Tremblay G Ste-Marie LG Brodt P Goltzman D Rabbani SA Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo Cancer Res 1994, 54:2372-2377. 8162583
92. Yi B Williams PJ Niewolna M Wang Y Yoneda T Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer Cancer Res 2002, 62:917-923. 11830552
93. Valta MP Hentunen T Qu Q Valve EM Harjula A Seppanen JA Vaananen HK Harkonen PL Regulation of osteoblast differentiation: A novel function for fibroblast growth factor 8 Endocrinology 2006, 147:2171-2182. 10.1210/en.2005-1502 16439448
94. Cramer SD Chen Z Peehl DM Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: Inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts J Urol 1996, 156:526-531. 10.1016/S0022-5347(01)65919-6 8683730
95. Kitagawa Y Dai J Zhang J Keller JM Nor J Yao Z Keller ET Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity Cancer Res 2005, 65:10921-10929. 10.1158/ 0008-5472.CAN-05-1809 16322239
96. Vakar-Lopez F Cheng CJ Kim J Shi GG Troncoso P Tu SM YuLee LY Lin SH Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow J Pathol 2004, 203:688-695. 10.1002/path.1568 15141384
97. Penolazzi L Magri E Lambertini E Calo G Cozzani M Siciliani G Piva R Gambari R Local in vivo administration of a decoy oligonucleotide targeting NF-kappaB induces apoptosis of osteoclasts after application of orthodontic forces to rat teeth Int J Mol Med 2006, 18:807-811. 17016609
98. Lev DC Kim SJ Onn A Stone V Nam DH Yazici S Fidler IJ Price JE Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice Clin Cancer Res 2005, 11:306-314. 15671560
99. Lara PN Jr Stadler WM Longmate J Quinn DI Wexler J Van Loan M Twardowski P Gumerlock PH Vogelzang NJ Vokes EE A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases Clin Cancer Res 2006, 12:1556-1563. 10.1158/1078-0432.CCR-05-2074 16533781